
John Stone MD
Vasculitis
Director, Clinical Rheumatology, Massachusetts General Hospital
Join to view full profile
55 Fruit Street/ Yawkey 2Boston, MA 02114
Phone+1 617-643-5385
Fax+1 617-643-1274
Dr. Stone is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California Division of Agriculture and Natural ResourcesMPh, Epidemiology, 1996
Harvard Medical SchoolClass of 1990
Oriel College, Oxford UniversityNo Degree, English Literature, 1986
Emory UniversityB.A., History, Cum Laude, 1985
University of California (San Francisco)Fellowship, Rheumatology
Certifications & Licensure
CA State Medical License 1993 - Present
MA State Medical License 2007 - 2028
RI State Medical License 2021 - 2028
ME State Medical License 2021 - 2027
NH State Medical License 2021 - 2027
MD State Medical License 1971 - 2007
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification Longitudinal Medical Record, Partners Healthcare System, 2013-2017
- CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2013-2017
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsPhase 3 Trial of Secukinumab in Polymyalgia Rheumatica.John H Stone, Frank Buttgereit, Alain Saraux, Wolfgang A Schmidt, Christian Dejaco
The New England Journal of Medicine. 2026-08-13 - A phase 2 trial of rilzabrutinib in IgG4-related disease.John H Stone, Mollie Carruthers, Matthew C Baker, Alireza Meysami, Robert Spiera
Annals of the Rheumatic Diseases. 2026-07-21 - Obexelimab for the Treatment of IgG4-Related Disease.Emanuel Della-Torre, Matthew C Baker, Wen Zhang, Cory A Perugino, Guy Katz
The New England Journal of Medicine. 2026-06-02
Journal Articles
- Health-Related Quality of Life in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Phase 3 Randomised Controlled TrialMicki Klearman, Vibeke Strand, John H Stone, BioMed Central
- RTX for IgG4-Related Disease: A Prospective, Open-Label TrialCarruthers MN, Topazian MD, Khosroshahi A, Witzig T, Wallace ZS, Hart P, Deshpande V, Smyrk T, Chari S, and Stone JH, Annals of the Rheumatic Diseases, 2/9/2015
- The prozone effect in serum assays for IgG4Khosroshahi A, Cheryk LA, Bloch DB, Stone JH, Arthritis & Rheumatology, 6/25/2014
Books/Book Chapters
Abstracts/Posters
- Wegener's granulomatosis mimicking renal cell carcinoma.Fairbanks K, Hellmann DB, Fishman E, Ali SZ, Stone JH, 2002 Year Book of Rheumatology, Arthritis, and Musculoskeletal Disease, 1/1/2002
- Outcome of renal transplantation in SLE: 97 Cyclosporine-Era patients and matched controls.Stone JH, Amend WJC, Criswell LA, 1999 Year Book of Medicine, 2000 Year Book of Rheumatology, 1/1/2000
- Frequency of recurrent lupus nephritis among 97 renal transplant patients from the cyclosporine era.Stone JH, Millward CL, Olson JL, Amend WJC, Criswell LA, 1999 Year Book of Medicine, 1/1/1999
Lectures
- ANCA-Associated Vasculitis: The way forward in treatment.New York, NY - 1/1/2015
- IgG4-Related Disease.Multiple Locations, 2008, 2009, 2010, 2011, 2012, 2013, 2014 - 3/20/2014
- IgG4-Related Disease: What the patients have taught us - so far.Multiple Locations, 2014 - 3/19/2014
Other
- Sen-pa-tsu and O-sa-e: B cell depletion in ANCA-associated vasculitis.Stone JH, Proceedings of the Research Committee on Intractable Vasculitis Syndromes of the Ministry of Health,
1/1/2008 - Clinical manifestations of vasculitic neuropathy.Brass SD, Stone JH, Helfgott SM, UpToDate
Wellesley, MA - 1/1/2007 - Clinical manifestations and diagnosis of scleritis.Stone JH, Dana MR, UpToDate
Wellesley, MA - 1/1/2007
Press Mentions
- Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review CourseOctober 28th, 2025
PeachJAM Connects Community in Fight Against Rare DiseaseSeptember 29th, 2025
Uplizna Becomes First Drug Approved for Rare Disease IgG4-RApril 4th, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









